Accelerated Resolution of Laser-Induced Bruising with SpeedGel Rx[®] A Rater-Blinded Randomized Controlled Trial

Gensco Laboratories, a leading manufacturer of transdermal medications, demonstrates in a randomized controlled trial that SpeedGel Rx[®] possesses superior results compared to a placebo in the treatment of bruises with no adverse systemic effects.

Trauma sufficient to cause bruising can occur from a wide variety of situations including accidents, falls, and surgeries. To the extent that bruises can occur on the face or exposed areas, and take days or weeks to resolve, they can be a problematic form of temporary disfigurement. Oral analgesics are commonly prescribed to treat bruising, but these agents often produce adverse systemic effects, which can be severe. Additionally, agents with the coagulative properties required to mitigate bruising may potentially induce undesirable systemic coagulative effects.

SpeedGel Rx[®] is a prescription homeopathic topically applied transdermal analgesic gel that provides an effective treatment for treating bruises. Non-steroidal topical agents, such as SpeedGel Rx[®], offer the potential to provide the same relief provided by oral analgesics but with minimal adverse systemic effects. Gensco Labs designed a randomized, double-blind, placebo-controlled trial to compare the efficacy of SpeedGel Rx[®] to a placebo in the prevention and resolution of laser induced bruising.

The study's primary aims were: (1) to determine the effectiveness of SpeedGel Rx^{e} in the reduction of pain in laser induced bruising over time, (2) to determine the effectiveness of SpeedGel Rx^{e} in the change of appearance of the bruise over time, and (3) to determine the effectiveness of SpeedGel Rx^{e} in the reduction of pigmented lesions that are monitored via a VISIATM complexion analysis tool over time.

Results demonstrate that SpeedGel Rx[®] reduced pain more quickly than placebo. On day two subjects were 6% more likely to experience pain using the placebo gel than SpeedGel Rx[®]. This increased to 15% at day four. SpeedGel Rx[®] also improved the appearance of the bruise more quickly than placebo. Subjects indicated a 10% quicker resolution in the color and appearance of the bruise using SpeedGel Rx[®].

This research indicates that SpeedGel Rx[®] is more effective than placebo in reducing the pain and negative appearance associated with bruising. The measurement of specific components of bruising, such as severity and burden of pain are often difficult to combine in a consistent way into the broader aspects of overall quality of life. Given that the goal of medical therapy for bruising focuses on improving aspects of a patient's life, the patient-reported outcomes reported here are important and accepted endpoints in clinical research trials. As such, health care professionals now have SpeedGel Rx[®] as a viable alternative to oral analgesics in the treatment of bruises.

Patrick Hardigan, BS, MS, PhD, Adjunct Professor- Oceanographic Center, Professor of Public Health, Director of the Statistical Consulting Center, Nova Southeastern University, Director of Clinical Research, Gensco Laboratories, 855-743-6726